✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Windlas Biotech Ltd.

WINDLAS

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹1,655 Cr.
P/E
24.58

Windlas Biotech Ltd.

  • Windlas Biotech
  • Bliss GVS Pharma
  • Shukra Pharma
  • TJI Pharma - Small Cap

FAQs on Windlas Biotech Ltd. Shareprice

Windlas Biotech has given better returns compared to its competitors.
Windlas Biotech has grown at ~29.38% over the last 4yrs while peers have grown at a median rate of 15.2%

Windlas Biotech is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Windlas Biotech is 24.67, while 3 year average PE is 25.08.
Also latest EV/EBITDA of Windlas Biotech is 15.88 while 3yr average is 14.07.

View FAQ's On Business

Growth Table

  • Windlas Biotech Ltd.
  • Bliss GVS Pharma
  • Shukra Pharma

Balance Sheet

  • Windlas Biotech Ltd.
  • Bliss GVS Pharma
  • Shukra Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Windlas Biotech Ltd.
  • Bliss GVS Pharma
  • Shukra Pharma

Cash Flow

  • Windlas Biotech Ltd.
  • Bliss GVS Pharma
  • Shukra Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Windlas Biotech Ltd.
  • Bliss GVS Pharma
  • Shukra Pharma

Quarterly Results

  • Windlas Biotech Ltd.
  • Bliss GVS Pharma
  • Shukra Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Windlas Biotech Ltd. Financials

Balance sheet of Windlas Biotech is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Windlas Biotech is increasing.
Latest net debt of Windlas Biotech is ₹10.86 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹4.72 Crs.

Yes, profit is increasing.
The profit of Windlas Biotech is ₹67.32 Crs for TTM, ₹60.99 Crs for Mar 2025 and ₹58.19 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Windlas Biotech latest dividend payout ratio is 19.93% and 3yr average dividend payout ratio is 19.74%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech